Table 3.
Association of plasma aldosterone concentration with risk of composite outcomes.
| PAC | Crude model | Model 1 | Model 2 | Model 3 |
|---|---|---|---|---|
| HR (95%CI) P value | HR (95%CI) P value | HR (95%CI) P value | HR (95%CI) P value | |
| Tertile 1 | Reference | Reference | Reference | Reference |
| Tertile 2 | 1.35 (1.04-1.75) 0.027 | 1.33 (1.02-1.74) 0.033 | 1.33 (1.02-1.73) 0.037 | 1.36 (1.04-1.78) 0.023 |
| Tertile 3 | 1.86 (1.45-2.38) < 0.001 | 1.76 (1.36-2.29) < 0.001 | 1.76 (1.36-2.28) < 0.001 | 1.81 (1.39-2.35) < 0.001 |
| P for trend | < 0.001 | < 0.001 | < 0.001 | < 0.001 |
| PAC+1ng/dl | 1.02 (1.01-1.03) < 0.001 | 1.02 (1.01-1.03) 0.016 | 1.01 (1.01-1.02) 0.019 | 1.01 (1.00-1.02) 0.009 |
| PAC+5ng/dl | 1.10 (1.05-1.15) < 0.001 | 1.06 (1.02-1.11) 0.016 | 1.06 (1.01-1.11) 0.019 | 1.07 (1.02-1.12) 0.009 |
| PAC+10ng/dl | 1.20 (1.10-1.32) < 0.001 | 1.13 (1.02-1.24) 0.016 | 1.12 (1.02-1.23) 0.019 | 1.14 (1.03-1.25) 0.009 |
Model 1: adjusted for age, T2DM at baseline, Duration of hypertension≥5 years, cigarette consumption, alcohol intake, waist circumference, SBP, DBP, eGFR, TG, HDL-C, Lp(a), serum potassium, PRA; Model 2: adjusted for gender, age, BMI, T2DM at baseline, Duration of hypertension≥5 years, cigarette consumption, alcohol intake, AHI≥15, waist circumference, SBP, DBP, eGFR, TC, TG, HDL-C, LDL-C, Lp(a), serum potassium, PRA; Model 3: Model2+ antihypertensive agents, statins, antiplatelet agents, regular CPAP treatment.